Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1185-1193

  Fang, Shu ^a   Wang, Zhehai ^b   Guo, Jun ^b   Liu, Jie ^b   Li, Changzheng ^b   Liu, Lin ^b   Shi, Huan ^b   Liu, Liyan ^b   Li, Huihui ^b   Xie, Chao ^b   Zhang, Xia ^b   Sun, Wenwen ^a   Li, Minmin ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Chemotherapeutic agents; Epidermal growth factor receptor mutation; Non small cell lung cancer; Prognosis; Targeted therapy

Indexed keywords

ARGININE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; LEUCINE; NAVELBINE; PEMETREXED; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DOSE RESPONSE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

EID: 84903987658     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S63665     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2 008. Int J Cancer. 2010;127:2893-2917.
2. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist. 2011;16:672-681.
3. Wu M, Zhao J, Song S W, et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2010;67:343-347.
4. Mok TS, Wu YL, Thongprasert S, et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
5. Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta analysis of 13 randomized trials. Clin Lung Cancer. 2012;2:107-114.
6. Giaccone G, Herbst RS, Manegold C, et al. Geftinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004;22:777-784.
7. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552.
8. Cappuzzo F, Ligorio C, Toschi L, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2:423-429.
9. Lee KH, Han S W, Hwang PG, et al. Epidermal growth factor response to chemotherapy in patients with non-small-cell lung cancer. Jpn J Clin Oncol. 2006;36:334-350.
10. Yoshimasu T, Oura S, Ohta F, et al. Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J Thorac Oncol. 2011;6:1658-1662.
11. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
12. Schiller JH, Harrington D, Belani C P, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
14. Dufort S, Richard MJ, Lantuejoul S, de Fraipont F. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res. 2011;30:57.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
16. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer. 2010;69:110-115.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med. 2004;350: 2129-2139.
18. Johnson ML, Sima CS, Chaft J, et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2013;119:356-362.
19. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909.
20. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;1:33-42.
21. Riely GJ, Pao W, Pham DK, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with geftinib or erlotinib. Clin Cancer Res. 2006;12:839-844.
22. Park JH, Lee SH, Keam B, et al. EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer. 2012;77:433-437.
23. Demarinis F, Paul S, Hanna N, et al. Survival update for the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer. J Clin Oncol. 2006;18:2241-2245.
24. Moro-Sibilot D, Vergneneqre A, Smit EF, et al. Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTION observational study. Curr Med Res Opin. 2010;26: 2661-2672.
25. Scagliotti G V, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
26. Peterson P, Simms L, Park K, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer. 2007;5:363-364.
27. Hotta K, Kiura K, Toyooka S, et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:632-637.
28. Sutani A, Nagai Y, Udagawa K, et al. Geftinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer. 2006;95:1483-1489.
29. Kim ES, Hirsh V, Mok T, et al. Geftinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809-1818.